Biomed. Papers 148(2), 161-166 (2004) | DOI: 10.5507/bp.2004.029

PHARMACOKINETICS AND BIODISTRIBUTION STUDIES OF DOXORUBICIN LOADED POLY(BUTYL CYANOACRYLATE) NANOPARTICLES SYNTHESIZED BY TWO DIFFERENT TECHNIQUES

L. Harivardhan Reddy, R. S. R. Murthy
Drug Delivery Research Laboratory, Center of Relevance and Excellence in NDDS, Pharmacy Department, G.H. Patel Building, Donor's Plaza, M.S. University, Fatehgunj, Baroda-390002, Gujarat, India

The aim of the study is to determine and compare the pharmacokinetics and tissue distribution of Doxorubicin (Dox) delivered as solution or through nanoparticles after intravenous (i.v.) and intraperitoneal (i.p.) injection. Doxorubicin loaded poly(butyl cyanoacrylate) nanoparticles were synthesized by dispersion polymerization (DP) and emulsion polymerization (EP) techniques. The drug loaded DP and EP nanoparticles were administered by i.v. or i.p. routes and the respective pharmacokinetics and tissue distribution were determined. Both types of nanoparticles significantly enhanced the elimination half-life (T1/2), mean residence time (MRT) AUC0-8, AUC0-∞ and AUMC0-8 of Dox in blood after i.v. injection. Dox delivered through DP nanoparticles rapidly disappeared from blood and distributed to the organs of reticuloendothelial system (RES). But, the clearance of Dox delivered through EP nanoparticles from blood was slower than this of the DP nanoparticles and Dox solution. After i.p. injection, the Dox loaded into DP nanoparticles quickly appeared in blood and undergone rapid distribution to the organs of RES, while the Dox loaded into EP nanoparticles absorbed slowly into blood and remained in the circulation for longer time. The absorption into blood of Dox delivered through DP and EP nanoparticles after i.p. injection was relatively rapid and higher than Dox solution. The T1/2, MRT, AUC0-8, AUC0-∞ and AUMC0-8 of Dox in blood were significantly higher and the clearance (Cl) was lower than for the Dox solution after i.p. injection. The tissue concentrations of Dox delivered through nanoparticles after i.p. injection were significantly lower than after i.v. injection. The bioavailability (F) of Dox was greatly enhanced by DP (∼1.9 fold) and EP nanoparticles (∼2.12 fold) compared to Dox solution after i.p. injection. EP nanoparticles significantly enhanced the bioavailability, MRT, T1/2, AUC0-8, AUC0-∞ and AUMC0-8 of Dox than DP nanoparticles. This signifies the advantage of EP nanoparticles in increasing the elimination half-life of Dox both after i.v. and i.p. injection and enhanced bioavailability after i.p. injection, which is expected to improve the therapeutic efficacy of Dox and reduce the Dox-associated systemic toxicity. Importantly, both DP and EP nanoparticles greatly reduced the distribution of Dox to heart both after i.v. and i.p. injection, suggesting their potential in reducing Dox-associated cardiotoxicity.

Keywords: Poly(butyl cyanoacrylate), Nanoparticle, Emulsion polymerization, Long circulating carrier, Pharmaco kinetics,

Received: May 10, 2004; Accepted: August 5, 2004; Published: December 1, 2004  Show citation

ACS AIP APA ASA Harvard Chicago IEEE ISO690 MLA NLM Turabian Vancouver
Reddy, L.H., & Murthy, R.S.R. (2004). PHARMACOKINETICS AND BIODISTRIBUTION STUDIES OF DOXORUBICIN LOADED POLY(BUTYL CYANOACRYLATE) NANOPARTICLES SYNTHESIZED BY TWO DIFFERENT TECHNIQUES. Biomedical papers148(2), 161-166. doi: 10.5507/bp.2004.029
Download citation

References

  1. Kreuter J. Nanoparticles. In: Kreuter J editor. Colloidal drug delivery systems, Marcel Dekker, New York, 1994. p. 219-342.
  2. Troster SD, Muller U, Kreuter J. (1990) Modification of the body distribution of poly(methyl methacrylate) nanoparticles in rats by coating with surfactants. Int J Pharm 61, 85-100. Go to original source...
  3. Grislain L, Couvreur P, Lenaerts V, Roland M, Deprez-Decampeneere D, Speiser P. (1983) Pharmacokinetics and biodistribution of a biodegradable drug-carrier. Int J Pharm 15, 335-345. Go to original source...
  4. Lowe PJ, Temple CS. (1994) Calcitonin and insulin in isobutyl cyanoacrylate nanocapsules: protection against proteases and effect of intestinal absorption in rats. J Pharm Pharmacol 46, 547-552. Go to original source... Go to PubMed...
  5. Verdun C, Couvreur P, Vranckx H, Lenaerts V, Roland M. (1986) Development of a nanoparticle controlled-release formulation for human use. J Cont Rel 3, 205-210. Go to original source...
  6. Sommerfeld P, Schroeder U, Sabel BA. (1997) Long-term stability of PBC nanoparticle suspensions suggests clinical usefulness. Int J Pharm 155, 201-207. Go to original source...
  7. Douglas SJ, Illum L, Davis SS, Kreuter J. (1984) Particle size and size distribution of poly(butyl-2-cyanoacrylate) nanoparticles I. Influence of physicochemical factors. J Colloid Interface Sci 101, 149-158. Go to original source...
  8. Douglas SJ, Davis SS, Illum L. (1986) Biodistribution of poly(butyl 2-cyanoacrylate) nanoparticles in rabbits. Int J Pharm 34, 145- 152. Go to original source...
  9. Harivardhan RL. Murthy RSR. (2003) Polymerization of n-butyl cyanoacrylate in presence of surfactant: study of influence of polymerization factors on particle properties, drug loading and evaluation of its drug release kinetics. Ars Pharmaceutica 44, 351-369.
  10. Proffitt RT, Williams LE, Presant CA, Tin GW, Ulina JA, Gamble RC, Baldeschwieler JD. (1983) Liposomal blockade of the reticuloendothelial system: improved tumor imaging with small unilamellar vesicles. Science 220, 502-505. Go to original source... Go to PubMed...
  11. Illum L, Davis SS. (1984) The organ uptake of intravenously administered colloidal particles can be altered using a non-ionic surfactant (Poloxamer 338). FEBS Lett 167, 79-82. Go to original source... Go to PubMed...
  12. Lue D, Manthey B, Kreuter J, Speiser P, Deluca PP. (1984) Distribution and elimination of coated polymethyl [2-14C) methacrylate nanoparticles after intravenous injection in rats. J Pharm Sci 73, 1433-1437. Go to original source... Go to PubMed...
  13. Storm G, Belliot SO, Daemen T, Lasic DD. (1995) Surface modification of nanoparticles to oppose uptake by the mononuclear phagocytic system. Adv Drug Del Rev 17, 31-48. Go to original source...
  14. Gulyaev AE, Gelperina SE, Skidan IN, Antropov AS, Kivman, GY, Kreuter J. (1999) Significant transport of doxorubicin into the brain with polysorbate 80-coated nanoparticles. Pharm. Res 16, 1564-1569. Go to original source... Go to PubMed...
  15. Peracchia MT, Fattal E, Desmaele D, Besnard M, Noel JP, Gomis JM, Appel M, dAngelo J, Couvreur P. (1999) Stealth PEGylated polycyanoacrylate nanoparticles for intravenous administration and splenic targeting. J Cont Rel 60, 121-128. Go to original source... Go to PubMed...
  16. Dembri A, Montisci M-J, Gantier jc, Chacun H, Ponchel G. (2001) Targeting of 3-Azido3-Deoxythymidine (AZT)-loaded Poly(isohe xylcyanoacrylate) nanospheres to the gastrointestinal mucosa and associated lymphoid tissues. Pharm Res 18, 467-473. Go to original source... Go to PubMed...
  17. Maeda H, Wu J, SAWA T, Matsumura y, Hori K. (2000) Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Cont Rel 65, 271-284. Go to original source... Go to PubMed...
  18. Jain RK. (2001) Delivery of molecular medicine to solid tumors: lessons from in vivo imaging of gene expression and function. J Cont Rel 74, 7-25. Go to original source... Go to PubMed...
  19. Duncan R. (1999) Polymer conjugates for tumor targeting and intracytoplasmic delivery. The EPR effect as a common gateway? Pharm Sci Tech Today 2, 441-249. Go to original source... Go to PubMed...
  20. Vigevani A, Williamson MJ. Doxorubicin. In: Florey K editor. Analytical profiles of drug substances. Academic Press, New York, 1980. p. 245-274. Go to original source...
  21. Reddy L.H. Murthy RSR. Fluorimetric estimation of Doxorubicin hydrochloride in plasma, whole blood and tissues of rat. Communicated.
  22. Reddy L.H. Murthy RSR. (2004) Influence of polymerization technique and experimental variables on particle properties and release kinetics of methotrexate from PBC nanoparticles. Acta Pharm In Press.